Hyperion Therapeutics, Inc. (HPTX) was a big mover last session, as its shares rose over 5% on the day. The rise came on solid volume too with far more shares changing hands than in a normal session. This reverses the downtrend for the company since Nov 29, as the stock is now down over 16%.
In the last 30 days, the company did not witness any estimate revision and the Zacks Consensus Estimate hasn’t been in a trend either. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Hyperion currently has a Zacks Rank #3 (Hold) while its Earnings ESP is negative.
Some better-ranked medical stocks include Lannett Company, Inc. (LCI), Jazz Pharmaceuticals plc (JAZZ) and Questcor Pharmaceuticals, Inc. (QCOR). All three companies carry a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment